培美曲塞二钠或多西他赛单药二线治疗晚期非小细胞肺癌的疗效和毒性分析  

Efficacy and Toxicity of Pemetrexed Disodium Combined with Docetaxel as Second-line Treatment for Advanced Non-small Cell Lung Cancer

作　　者：田洁[1] 张媛[1] 俞邓枝 陈杰[1] 

机构地区：[1]安徽省淮南朝阳医院,232007

出　　处：《实用癌症杂志》2017年第7期1146-1148,共3页The Practical Journal of Cancer

摘　　要：目的探讨培美曲塞二钠或多西他赛单药二线治疗晚期非小细胞肺癌的疗效和毒性。方法选择48例经一线化疗失败的晚期NSCLC患者,按照随机数表法将其分为2组。2组分别实施培美曲塞二钠、多西他赛单药治疗,观察治疗后的不良反应、近期及远期疗效。结果 2组患者化疗后的近期疗效以及远期疗效比较,差异不具有统计学意义(P>0.05);而培美曲塞二钠组患者化疗后的不良反应远低于多西他赛组,差异具有统计学意义(P<0.05)。结论培美曲塞二钠在保证对NSCLC的临床治疗效果的同时可以降低其不良反应。Objective To investigate the efficacy and toxicity of pemetrexed disodium or docetaxel second-line treatment for advanced non-small cell lung cancer（NSCLC）. Methods Select 48 NSCLC patients who failed first-line chemotherapy, and then randomly divided into 2 groups. The 2 groups were respectively treated with pemetrexed disodium and docetaxel . Then observed the side effects,short-term and long-term effects. Results Short-term efficacy and long-term efficacy of the 2 groups had no statistically significant difference （ P 〉 0.05 ） ; and adverse reactions of pemetrexed group after chemotherapy was much lower than that of docetaxel group, the difference was statistically significant （ P 〈 0.05 ）. Conclusion Pemetrexed disodium for NSCLC can significantly improve the clinical efficacy and reduce adverse reaction.

关 键 词：培美曲塞二钠 多西他赛 非小细胞肺癌 疗效 毒性 

分 类 号：R734.2[医药卫生—肿瘤]